Medytox said that a high-level delegation led by Dubai Science Park, owned by Tecom Group, a state-run company in Dubai, has conducted due diligence on its second and third botulinum toxin (BTX) manufacturing plants in Osong, North Chungcheong Province.

The Dubai Science Park visit to Korea follows the two companies signing a memorandum of understanding (MOU) last month on establishing a BTX manufacturing plant in the UAE. At the same time, Medytox participated in the UAE economic delegation of President Yoon Suk-yeol.

The Dubai Science Park delegation conducted due diligence on Medytox's second plant, a production facility that received U.S. FDA's current good manufacturing (cGMP) and European Medicines Agency (EMA)'s GMP certification.

The delegation also visited Medytox's third plant, the company's newest factory that manufactures BTX and filler production facilities.

"We have a great sense of responsibility in establishing Korea's first overseas BTX production base," Medytox CEO Jung Hyun-ho said. "As discussions are accelerating after participating in the UAE economic delegation, we will do our best to complete the deal."

Dubai Science Park CEO Marwan Abdulaziz Janahi also said, "Dubai's bio-industry is a major growth engine in the region thanks to the outstanding capabilities of global companies."

Medytox's excellent R&D capabilities and know-how will positively contribute to the growth of the Dubai bio industry based on Dubai's R&D strategy emphasizing innovation and manufacturing, he added.

Janahi stressed that with the establishment of Medytox's plant, he expects the cooperative relationship between the two countries to continue to expand.

In parallel with the two-day due diligence, Medytox and DSP also met with officials from the Ministry of Food and Drug Safety to discuss ways to support and nurture Korean companies entering the Middle East, and strengthen cooperation in the bio sector between the two nations.